A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Trial Profile

A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors BriaCell Therapeutics Corp
  • Most Recent Events

    • 23 Apr 2018 According to a BriaCell Therapeutics media release, Sylvester Comprehensive Cancer Center at the University of Miami, is now actively screening and enrolling patients. Dr. Carmen Julia Calfa, a board certified medical oncologist, will be the principal investigator of the study at this site.
    • 18 Apr 2018 Preliminary data published in the BriaCell Therapeutics Media Release
    • 18 Apr 2018 According to a BriaCell Therapeutics media release, the company has presented preliminary data, at the 2018 American Association of Cancer Research (AACR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top